-
Mashup Score: 0
Abstract. Background: National Comprehensive Cancer Network guidelines have recommended metastatic colorectal cancer patients (mCRC pts) undergo BRAF, KRAS, NRAS, and microsatellite instability/mismatch repair deficiency (MSI/MMR) testing since 2015. Previous studies have reported molecular testing rates from academic and community cancer centers, but there is a lack of information on testing…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Abstract. Background: National Comprehensive Cancer Network guidelines have recommended metastatic colorectal cancer patients (mCRC pts) undergo BRAF, KRAS, NRAS, and microsatellite instability/mismatch repair deficiency (MSI/MMR) testing since 2015. Previous studies have reported molecular testing rates from academic and community cancer centers, but there is a lack of information on testing…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Staged analysis of standard of care tumor molecular testing among patients with metastatic colorectal cancer in the community health system setting [Jul 2021] Zhang et al. @TDBrownMD Abstract 2618 #AACR21 https://t.co/mKe1YfsySU #PrecisionMedicine #crcsm #camets https://t.co/lgRAMiyLcR
-
-
Mashup Score: 0
Abstract. Background: National Comprehensive Cancer Network guidelines have recommended metastatic colorectal cancer patients (mCRC pts) undergo BRAF, KRAS, NRAS, and microsatellite instability/mismatch repair deficiency (MSI/MMR) testing since 2015. Previous studies have reported molecular testing rates from academic and community cancer centers, but there is a lack of information on testing…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Staged analysis of standard of care tumor molecular testing among patients with metastatic colorectal cancer in the community health system setting [Jul 2021] Zhang et al. @TDBrownMD Abstract 2618 #AACR21 https://t.co/mKe1Yfs13m #PrecisionMedicine #crcsm #camets
-
-
Mashup Score: 0
Abstract. Background: National Comprehensive Cancer Network guidelines have recommended metastatic colorectal cancer patients (mCRC pts) undergo BRAF, KRAS, NRAS, and microsatellite instability/mismatch repair deficiency (MSI/MMR) testing since 2015. Previous studies have reported molecular testing rates from academic and community cancer centers, but there is a lack of information on testing…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Staged analysis of standard of care tumor molecular testing among patients with metastatic colorectal cancer in the community health system setting [Jul 2021] Zhang et al. @TDBrownMD Abstract 2618 #AACR21 https://t.co/mKe1Yfs13m #PrecisionMedicine #crcsm #camets
-
-
Mashup Score: 0
Dabrafenib plus trametinib showed clinically meaningful activity in patients with BRAFV600E mutation-positive recurrent or refractory high-grade glioma and low-grade glioma, with a safety profile consistent with that in other indications. BRAFV600E testing could potentially be adopted in clinical practice for patients with glioma.
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
From oral presentation #aacr21 to @TheLancetOncol publication 👉 Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial @AACR #AACR22 https://t.co/0p6SieOcJO
-
-
Mashup Score: 1
Abstract. Background: National Comprehensive Cancer Network guidelines have recommended metastatic colorectal cancer patients (mCRC pts) undergo BRAF, KRAS, NRAS, and microsatellite instability/mismatch repair deficiency (MSI/MMR) testing since 2015. Previous studies have reported molecular testing rates from academic and community cancer centers, but there is a lack of information on testing…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Staged analysis of standard of care tumor molecular testing among patients with metastatic colorectal cancer in the community health system setting [Jul 2021] Zhang et al. @TDBrownMD Abstract 2618 #AACR21 https://t.co/mKe1Yfs13m #PrecisionMedicine #crcsm #camets https://t.co/7stOf2neBW
-
-
Mashup Score: 0
Immunotherapy together with an experimental cancer drug could offer a new way of treating some patients with aggressive brain cancers, promising early results from a Phase I trial presented at the 2021 AACR conference suggest.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
1️⃣ In April, our researchers presented early data from a Phase I trial at #AACR21 suggesting that #Immunotherapy with an experimental cancer drug could be a new way to treat some people with aggressive #BrainCancer. 🧠 @AACR @royalmarsdenNHS @ICR_DDU_IIT https://t.co/RRhWOSqFDG
-
-
Mashup Score: 1
Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA Background: National Comprehensive Cancer Network guidelines have recommended metastatic colorectal cancer patients (mCRC pts) undergo BRAF, KRAS, NRAS, and microsatellite instability/mismatch repair deficiency (MSI/MMR) testing since 2015. Previous studies have reported molecular testing rates from…
Source: Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Staged analysis of standard of care tumor molecular testing among patients with metastatic colorectal cancer in the community health system setting [Jul 2021] Zhang et al. @TDBrownMD Abstract 2618 #AACR21 https://t.co/mKe1Yfs13m #PrecisionMedicine #crcsm #camets https://t.co/mdp5jjIOcJ
-
-
Mashup Score: 0Medscape Log In - 2 year(s) ago
Free Unlimited Access and Benefits: Latest medical news and expert perspectives Essential drugs, diseases, and clinical tools Free CME and professional online education
Source: login.medscape.comCategories: General Medicine News, Latest HeadlinesTweet-
Systemic lupus erythematosus updates from #AACR21 discussed by Dr Joan Merrill, who reviews data on a novel agent, a post-hoc analysis of BLISS-LN, and late-breaking BLISS-BELIEVE results. https://t.co/chu6dtIBFn https://t.co/jpWrlnM6iD
-
-
Mashup Score: 0Guiju Sun Bio | American Association for Cancer Research - 2 year(s) ago
Q: What is your primary area of study/research? A: Nutrition and chronic disease (including cancer); the effects of different fatty acids on human health; phytochemicals; food efficacy; cancer epidemiology; nutritional epidemiology. Q: What influenced your decision to embark on a research career? A: My interest in scientific research drives me to embark on a research career. I hope to…
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
If you haven't read the Best of Author Profile featuring a Q&A with CAPR author Guiju Sun, then check it out now: https://t.co/0rGZc66BVp #AACR21 https://t.co/QhyrcUxMFU
-
Staged analysis of standard of care tumor molecular testing among patients with metastatic colorectal cancer in the community health system setting [Jul 2021] Zhang et al. @TDBrownMD Abstract 2618 #AACR21 https://t.co/mKe1YfsySU #PrecisionMedicine #crcsm #camets https://t.co/b7O5O74C3B